BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 48 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,608,000 | +39.7% | 1,500,000 | +61.3% | 0.20% | +23.1% |
| Q2 2020 | $1,151,000 | -75.3% | 930,000 | -79.1% | 0.16% | -71.4% |
| Q1 2020 | $4,664,000 | +48.9% | 4,450,000 | +50.8% | 0.56% | +115.4% |
| Q4 2019 | $3,133,000 | -1.0% | 2,950,000 | -8.1% | 0.26% | +3.2% |
| Q3 2019 | $3,166,000 | -90.1% | 3,210,000 | -89.5% | 0.25% | -91.1% |
| Q2 2019 | $32,001,000 | -6.3% | 30,715,000 | -7.4% | 2.82% | -12.5% |
| Q1 2019 | $34,170,000 | +2.7% | 33,175,000 | -0.2% | 3.23% | -10.3% |
| Q4 2018 | $33,275,000 | -7.4% | 33,255,000 | -2.0% | 3.60% | +15.6% |
| Q3 2018 | $35,929,000 | +25.3% | 33,935,000 | +20.3% | 3.11% | +36.3% |
| Q2 2018 | $28,681,000 | +19.0% | 28,205,000 | +10.4% | 2.28% | +47.2% |
| Q1 2018 | $24,103,000 | +488.6% | 25,540,000 | +522.9% | 1.55% | +544.0% |
| Q4 2017 | $4,095,000 | – | 4,100,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |